Monitoring of therapy progress in patients with gynecological tumor disease or breast cancer using peripheral biomarkers

• Conditions: Breast cancerOvarian cancerEndometrial cancerCervical CancerVulvar cancerVaginal Cancer; C51-C58; C50; Malignant neoplasms of female genital organs; Malignant neoplasm of breast

• Registration Number: DRKS00023293
• Lead Sponsor: Frauenklinik - Klinikum Hanau

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 500

Inclusion Criteria

Coming of age
- Proven gynecological malignant disease

Exclusion Criteria

- patients under 18 years
- patients not being contractually capable
- patients without existing written consent
- patients who recanted their written consent
- clinically apparent anemia

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary goal is the investigation of new tumor markers or multiplex assays for various malignant diseases.<br><br>The advised number of patients is for:<br>- Breast cancer 200 - 250 patients, each with a complete sample series<br>- Ovarian cancer ~ 50 patients with one complete sample series each<br>And for other gynecological malignancies (endometrium / cervical / vulvar / vagina) about 20 - 30 per entity.<br><br>The collection period is initially limited to 24 months, but can be extended until the target is reached if the notified number of samples is not reached.

Secondary Outcome Measures

Name	Time	Method
no secondary outcome